Biotech: Centogene gibt Debüt an der New Yorker Börse (Seite 3)

[max-gewinner]

Antwort auf Beitrag Nr.: 70.079.024 von erwin-kostedde am 30.11.21 21:07:02

oder woanders:

https://www.vitalab-shop.de/pcr-laborgeraet/

https://youtu.be/MawxrOO4oeA

Beteiligung leider nur über die sehr undurchsichtige Verbindung zu/mit/über nanorepro möglich

[erwin-kostedde]

RKI vom 30.11.21:
Seit KW 45/2021 hat die Anzahl der wöchentlich durchgeführten PCR-Tests auf SARS-CoV-2 stark zugenommen; in einigen Regionen befinden sich Labore an den Grenzen ihrer Auslastung. Daher ist eine Priorisierung des Einsatzes von PCR-Tests gemäß der Nationalen Teststrategie aktuell geboten.

Die Anlässe zu einer PCR-Testung sollten unter dem Aspekt der regional verfügbaren PCR-Kapazitäten entsprechend kritisch geprüft werden. Dazu zählt z.B. auch eine Begrenzung der Anwendung von PCR-Tests im Rahmen einer ggf. angestrebten Verkürzung der Quarantänezeit von Kontaktpersonen und bei der Entisolierung.

Für depriorisierte Anlässe (gemäß Teststrategie) sollten bei gebotener Indikation hochwertige Antigenschnelltests eingesetzt werden.

dann sollte es ja eigentlich laufen bei Centogene

[Hanspeterdergrosse]

Ich denke, bestenfalls die Genomdatenbank hat gewissen Wert. Das Personal ist eher auswechselbar, da da Standard-Verfahren zu Anwendung kommen. Aber so wie die Lage derzeit ist, dürften auch in 2022 horrende Verluste anfallen.

[erwin-kostedde]

Antwort auf Beitrag Nr.: 70.040.449 von Hanspeterdergrosse am 26.11.21 14:37:06

oder die Übernahme durch jemanden, der mehr Geld hat.
Ich weiß aber nicht, ob das know how von Centogene als company für die Mitbewerber interessant ist.

[Hanspeterdergrosse]

Bei dem Cash-Burn wird dann in absehbarer Zeit wieder eine Kapitalerhöhung fällig.

[Hanspeterdergrosse]

Richtig schlecht

[erwin-kostedde]

da sind sie:

CENTOGENE Reports Third Quarter 2021 Financial Results
November 24, 2021 at 7:36 AM EST
Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update.

Executive Commentary

“We are encouraged by the progress achieved in Q3 on our continued path to return focus and growth to our rare disease business, driving strategic Core Business execution,” stated Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. “We saw continued recovery trends in the Diagnostics segment, with over 40% increase in revenues compared to Q3 2020. While recovery in Pharma revenues is lagging, we remain optimistic for acceleration in the fourth quarter, given the ongoing growth in signed contract value as our new management team gains traction with current and prospective Pharma partners.”

Q3 Financial Highlights

Overall revenues of €30.2 million in Q3 2021, a 17% decrease compared to €36.3 million in Q3 2020
Revenues from the Company’s Pharma and Diagnostics segments (“Core Business”) increased 13%, including Diagnostics revenues (excl. COVID) of €7.3 million, an increase of 43% compared to €5.1 million in Q3 2020, and Pharma revenues of €2.7 million in Q3 2021, a decrease of 28% compared to €3.8 million in Q3 2020
Commercial COVID-19 testing revenues of €20.2 million in Q3 2021, down from €27.4 million in Q3 2020
Total segment adjusted EBITDA of €(2.5) million compared to €9.2 million in Q3 2020 from the Company’s Pharma, Diagnostics, and COVID-19 testing segments, mainly reflecting the adjusted EBITDA contribution from COVID-19 testing having decreased by €13.4 million compared to the same quarter last year, partially offset by stronger adjusted EBITDA contribution from the Core Business segments
Cash and cash equivalents of €25.7 million as of September 30, 2021, compared to €34.8 million for the period ending June 30, 2021. There is uncertainty about the Company's ability to continue as a going concern. Please refer to the Company's Q3 2021 interim financial statements and related disclosures.

[erwin-kostedde]

CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

[erwin-kostedde]

Offenbar haben ein paar Leute das nemj gelesen. Gut so

https://investors.centogene.com/news-releases/news-release-d…

[erwin-kostedde]

Q2 Zahlen vom 07.09.:

Q2 Financial Highlights

Revenues of €51.9 million in Q2 2021, a 434% increase compared to €9.7 million in Q2 2020; Revenues from the Company’s Pharma and Diagnostics segments (“Core Business”) increased 25%
Clinical Diagnostics revenues (excl. COVID) of €6.7 million, an increase of 82% compared to €3.6 million in Q2 2020
Pharma revenues of €2.8 million in Q2 2021, down from €3.9 million in Q2 2020, with further revenues weighted towards the end of 2021
Commercial COVID-19 testing revenues of €42.3 million in Q2 2021, up from €2.1 million in Q2 2020
Positive total segment adjusted EBITDA of €7.5 million compared to €1.0 million in Q2 2020 from the Company’s Pharma, Diagnostics, and COVID-19 testing segments
Cash and cash equivalents of €34.8 million as of June 30, 2021, compared to €45.2 million for the period ending March 31, 2021

https://investors.centogene.com/news-releases/news-release-d…